K4 Elite logo K4 Elite
Home / Peptide Library / Prostamax
Emerging Research

Prostamax

Hormonal & Endocrine · ['Prostamax (Cytomax)', 'Prostate peptide bioregulator', 'Prostate peptide complex']

A peptide-complex bioregulator derived from prostate tissue, studied in Russian literature for proposed effects on prostate tissue function and related endocrine parameters.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Research Level
Emerging Research
Browse the store →
🧬

Prostamax is a peptide-complex bioregulator in the Khavinson tradition, described as being derived from prostate tissue. It is related to the more extensively studied preparation Prostatilen/Prostatilen-family peptides and to short prostate peptides investigated in Russian andrology and gerontology research.

Within the tissue-specific bioregulator framework, Prostamax is associated with prostate tissue and the male reproductive and endocrine systems. As a tissue-derived complex rather than a single characterized molecule, it lacks a consistently reported structure or PubChem identifier.

Molecular fields are therefore left blank. The information below summarizes available scientific literature for reference purposes only.

In the Khavinson-school framework, short prostate-derived peptides are proposed to act as tissue-specific regulators of gene expression, with reported laboratory effects on prostate epithelial and stromal parameters and on microcirculation markers in animal models.

These mechanistic descriptions come largely from the originating research programs and remain hypotheses under continuing investigation rather than broadly independently validated pathways.

  • Prostate tissue function and morphology in animal models
  • Peptide bioregulation and tissue-specific gene-expression hypotheses
  • Microcirculation and inflammation parameters in prostate research
  • Male reproductive and endocrine-axis investigations
  • Geroprotective peptide research in aging models
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Research on prostate peptide bioregulators (including the related Prostatilen preparation) has been reported in Russian urology and gerontology literature, describing effects on prostate tissue parameters and inflammatory markers in animal and clinical studies. These are summarized strictly as published exploratory findings.

Review work by Khavinson and colleagues situates prostate peptides within the cytomax bioregulator framework, describing proposed tissue-restorative activity observed in laboratory settings rather than in large controlled independent trials.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Testosterone-pathway agentsCaution
Both relate to male endocrine function through distinct mechanisms; combined effects are not characterized in the literature.
EpitalonCompatible
A pineal peptide bioregulator studied alongside tissue complexes in aging research.
Vesugen / vascular peptidesNeutral
Related short-peptide bioregulators with distinct tissue targets.
Anti-inflammatory small moleculesNeutral
Overlapping research themes in prostate inflammation; interactions are not well described.
  1. Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett 2002
  2. Anisimov VN, Khavinson VK. Peptide Bioregulation of Aging: Results and Prospects. Biogerontology 2010
  3. Khavinson VK et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021
What is Prostamax?
It is a prostate-tissue-derived peptide complex from the Khavinson family of bioregulators, studied for proposed effects on prostate tissue and related endocrine parameters.
Why are molecular fields blank?
Prostamax is described as a multi-peptide complex rather than a single defined molecule, and no verified PubChem identifier is consistently reported, so no molecular data is fabricated here.
How robust is the evidence?
Most published data comes from a limited set of research groups, so Prostamax is classified as an emerging-research compound pending broader independent study.
How is it related to Prostatilen?
It belongs to the same family of prostate-derived peptide preparations investigated in Russian urology and gerontology literature.
Is this material for human or veterinary use?
No. It is supplied strictly as a research-use-only reference material and is not intended for human consumption, medical treatment, or veterinary application.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.